Bharat Biotech in tie-up with FluGen to develop ‘CoroFlu’ vaccine

Sumit Arora Last updated on April 11th, 2020 02:09 pm Leave a comment

Bharat Biotech in tie-up with the US-based company FluGen and University of Wisconsin Madison to develop a vaccine named “Coro-Flu” to fight against COVID-19. CoroFlu will build on the backbone of FluGen’s flu vaccine candidate known as M2SR.

Click Here To Get Test Series For SBI PO 2020

The vaccine is being developed on the basis of FluGen’s flu vaccine candidate known as M2SR, a self-limited version of the influenza virus. It induces an immune response against the flu. The vaccine will be built by FluGen’s lab that inserts gene sequences from SARS-CoV-2, the novel coronavirus that causes the disease COVID-19 into M2SR so that the novel vaccine will also induce immunity against the coronavirus.

Important takeaways for all competitive exams:

Headquarters of Bharat Biotech: Hyderabad,Telangana.
Chairman and Managing Director of Bharat Biotech: Krishna M Ella.

Find More News Related to Agreements

About the Author

Sumit Arora

Author

As a team lead and current affairs writer at Adda247, I am responsible for researching and producing engaging, informative content designed to assist candidates in preparing for national and state-level competitive government exams. I specialize in crafting insightful articles that keep aspirants updated on the latest trends and developments in current affairs. With a strong emphasis on educational excellence, my goal is to equip readers with the knowledge and confidence needed to excel in their exams. Through well-researched and thoughtfully written content, I strive to guide and support candidates on their journey to success.